Skip to main content

Advertisement

SpringerLink
Log in

Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay

  • SHORT REPORT
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Aapro M et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420–432

    Article  CAS  PubMed  Google Scholar 

  2. Body JJ (2006) Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 14(5):408–418

    Article  PubMed  Google Scholar 

  3. Costa L (2007) Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast 16(Suppl 3):S16–S20

    Article  PubMed  Google Scholar 

  4. Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):3–13

    Article  CAS  PubMed  Google Scholar 

  5. Knight LA et al (2005) Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs 16(9):969–976

    Article  CAS  PubMed  Google Scholar 

  6. Hirabayashi H, Fujisaki J (2003) Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents. Clin Pharmacokinet 42(15):1319–1330

    Article  CAS  PubMed  Google Scholar 

  7. Sturtz GL et al (1993) Synthesis of gem-bisphosphonic methotrexate conjugates and their biological response towards Walker’s osteosarcoma. Eur J Med Chem 28(11):899–903

    Article  CAS  Google Scholar 

  8. Fabulet O, Sturtz GA (1995) Synthesis of gem-bisphosphonic doxorubicinconjugates. Phosphorus Sulfur Silicon Relat Elem 101(1–4):225–234

    Article  CAS  Google Scholar 

  9. Klenner T et al (1990) Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo. Cancer Treat Rev 17(2–3):253–259

    Article  CAS  PubMed  Google Scholar 

  10. Reinholz MM et al (2010) A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone 47(1):12–22

    Article  CAS  PubMed  Google Scholar 

  11. Papapoulos SE (2006) Bisphosphonate actions: physical chemistry revisited. Bone 38(5):613–616

    Article  PubMed  Google Scholar 

  12. Andreotti PE et al (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55(22):5276–5282

    CAS  PubMed  Google Scholar 

  13. Gerhardt RT et al (1991) Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. Am J Obstet Gynecol 165(2):245–255

    CAS  PubMed  Google Scholar 

  14. Kangas L, Gronroos M, Nieminen AL (1984) Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 62(6):338–343

    CAS  PubMed  Google Scholar 

  15. Konecny G et al (2000) Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77(2):258–263

    Article  CAS  PubMed  Google Scholar 

  16. Kurbacher CM et al (1998) Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 9(1):51–57

    Article  CAS  PubMed  Google Scholar 

  17. Neubauer H et al (2008) Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 28(2A):949–955

    PubMed  Google Scholar 

  18. Schott S et al (2009) ATP chemosensitivity testing of new antitumor duplex drugs linking 3;-C-ethynylycytidine (ECyd) and 2 -deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof. Invest New Drugs

  19. Sevin BU et al (1988) Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31(1):191–204

    Article  CAS  PubMed  Google Scholar 

  20. Sharma S et al (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19

    Article  PubMed  Google Scholar 

  21. Rajala P et al (1992) Cytostatic effect of different strains of Bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol Res 20(3):215–217

    Article  CAS  PubMed  Google Scholar 

  22. Laaksovirta S et al (1999) The cytostatic effect of 9-cis-retinoic acid, tretinoin, and isotretinoin on three different human bladder cancer cell lines in vitro. Urol Res 27(1):17–22

    Article  CAS  PubMed  Google Scholar 

  23. Monkkonen H et al (2008) Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 19(4):391–399

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynaecology and Obstetrics, National Center for Tumour Diseases (NCT) , University of Heidelberg, 69115, Heidelberg, Germany

    Sarah Schott & Markus Wallwiener

  2. Department of Gynaecology and Obstetrics, University of Tuebingen, 72076, Tuebingen, Germany

    Beate Kootz, Harald Seeger, Tanja Fehm & Hans Neubauer

  3. Calwerstr. 7/6, 72076, Tuebingen, Baden-Wuerttemberg, Germany

    Hans Neubauer

Authors
  1. Sarah Schott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Wallwiener
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beate Kootz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harald Seeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tanja Fehm
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans Neubauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Neubauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schott, S., Wallwiener, M., Kootz, B. et al. Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay. Invest New Drugs 30, 1750–1755 (2012). https://doi.org/10.1007/s10637-011-9688-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-011-9688-3

Keywords

Search

Navigation